[In unipolar depression does the response to the dexamethasone suppression test predict a symptomatic recurrence after clinical cure?].
We assessed the length and the quality of the remission of 13 unipolar endogenous depressed DST nonsuppressors before treatment in a 2-year prospective study. During this period, we recorded stressful life events. Persistent dexamethasone non-suppression after treatment and complete clinical recovery correlated highly with early clinical relapse. All six nonnormalizers but only one normalizer were rehospitalized within the following two years for a major depressive relapse. Persistent DST nonsuppression was unrelated to any impact of drug discontinuation, to the occurrence of stressful life events or to the length of illness-free intervals in the patient's prior course of illness. Persistent DST non-suppression appears to have a significant prognostic value.
D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000175:diagnosis* / Q000628:therapy; D003907:Dexamethasone; D005260:Female; D006760:Hospitalization; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D011379:Prognosis; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012008:Recurrence
D003907:Dexamethasone; D006854:Hydrocortisone
Dans la dépression unipolaire, la réponse au test de freination à la dexaméthasone après guérison clinique prédit-elle une rechute symptomatique?